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Abstract
Background Capecitabine monotherapy is a treatment
option for selected patients with metastatic colorectal
cancer (mCRC) and is administered to up to 17% of
patients. Data are limited with regard to adverse events and
dosing practices associated with capecitabine monotherapy
in real-world situations.
Objectives The aim of this study was to provide real-world
data on adverse event rates and dose adjustments/discon-
tinuations associated with capecitabine monotherapy in
patients with mCRC.
Methods This retrospective study analyzed data from CRC
patients scheduled to receive up to eight planned cycles of
capecitabine monotherapy between 2009 and 2013 at a
single large community hospital in The Netherlands. Data
on adverse events (hand-foot syndrome [HFS], gastroin-
testinal (GI) events, hematological adverse events, and
cardiotoxicity), as well as relative dose intensities (RDIs),
dose reductions, and discontinuations, were evaluated.
Results Data from 86 patients (45 females; mean age at the
start of treatment, 69 years) were included. A total of
46.5% of patients experienced HFS and 44.2% experienced
a GI event at some time during treatment. Hematological
events and cardiotoxicity were rare. Most patients (77%)
started at below the recommended dose, and patients at the
lowest dose also had the lowest median RDIs. Dose
reductions and discontinuations occurred in 15–25% of
patients who experienced HFS or GI event over the course
of eight cycles.
Conclusions HFS and GI events were very common in
patients treated with capecitabine monotherapy in a real-
world clinical setting. Most patients started treatment at
below the recommended dose, and 15–25% of patients who
had HFS or a GI event had a dose reduction or
discontinuation.
Key Points
This study provides real-world data on adverse
events and dosing practice associated with
capecitabine monotherapy in patients with metastatic
colorectal cancer.
Hand-foot syndrome and gastrointestinal (GI) events
were seen in almost half of the patients treated with
capecitabine monotherapy.
Dose reductions and discontinuations occurred in
15–25% of patients who experienced hand-foot
syndrome or GI events over the course of eight
cycles of therapy.
1 Introduction
Fluoropyrimidine monotherapy is a recommended
chemotherapeutic treatment option for patients with
metastatic colorectal cancer (mCRC) who are frail or may
not tolerate more aggressive therapy [1–3]. Oral
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capecitabine provides a convenient alternative to the
standard intravenous fluoropyrimidine, 5-fluorouracil. In
clinical trials, oral capecitabine monotherapy has been
shown to be as effective as intravenous 5-fluorouracil as
first-line treatment for mCRC, and is generally associated
with an improved safety profile with lower rates of stom-
atitis, alopecia, diarrhea, nausea, and grade 3/4 neutropenia
[4–7]; however, reported rates of hand-foot syndrome
(HFS) are higher with capecitabine. HFS is characterized
by erythema, dysesthesia and/or paresthesia of the palms of
the hands or soles of the feet. In more advanced stages,
desquamation, ulceration, and blistering can occur. HFS
occurs in approximately 54% of patients (17% grade 3/4)
who receive capecitabine treatment [4, 6–8]. Grade 3/4
hyperbilirubinemia is also higher with capecitabine and
occurs in approximately 23% of patients [4, 6, 7]. The
approved regimen for capecitabine is 1250 mg/m2 twice
daily for 14 days, followed by 7 days off [9]. In phase III
trials, 34% of patients received a reduced dose due to the
occurrence of adverse events [4].
In phase III trials including older patients ([70 years of
age), who represent a key group in which capecitabine
monotherapy may be indicated, grade 3/4 adverse events
occurred in 12–22% of patients, including grade 3/4 HFS,
diarrhea, venous thromboembolism, neutropenia, throm-
bocytopenia, and hemorrhage [8, 10]. Eighteen percent of
elderly patients experience dose delays due to adverse
events while receiving capecitabine monotherapy and 15%
discontinue treatment due to adverse events [8, 10].
Most real-world studies of physician prescribing pat-
terns in mCRC have focused on the impact of effective
biologic and combination treatments that have extended
survival in mCRC in recent years [11–13]. These analyses
of retrospective data of treatment patterns have reported
that 9–17% of patients receive capecitabine monotherapy
as first-line treatment, 5–9% as second-line treatment, and
as many as 17% receive this regimen as third-line treatment
[11–13]. An observational study of capecitabine-based
therapy in routine first-line treatment of mCRC reported
that 56% of patients received capecitabine-based treat-
ment—54% of these as combination therapy and 46% of
these as monotherapy. Of patients who received
monotherapy, 65% were older than 75 years of age [14].
Rates of grade 3/4 adverse events associated with capeci-
tabine monotherapy were highest for HFS, bilirubin ele-
vation, anemia, and neuropathy, which all occurred in 4%
of patients [14].
Despite these few studies, real-world data are limited
with regard to the adverse events and dosing practice
associated with oral capecitabine monotherapy in mCRC in
the oncology clinic. While realizing its inherent limitations,
this study sought to provide real-world data on the occur-
rence of adverse events in patients treated with
capecitabine monotherapy for mCRC at a single large
community hospital.
2 Methods
This was a single-center, retrospective study of patients
treated at a large community hospital in Zwolle, The
Netherlands, for mCRC. Data were collected for toxicity in
relation to dose and exposure time for patients diagnosed
with adenocarcinoma. We limited our period of analysis to
the planned eight cycles (±6 months) of capecitabine
monotherapy, as recommended in the Dutch pharma-
cotherapeutic guidelines for capecitabine monotherapy in
mCRC. In these guidelines, capecitabine monotherapy is
considered a good option when no immediate response is
needed (for instance in case of relatively limited tumor
load), or in patients who are deemed too frail to start with
combination therapy.
Institutional Review Board approval was obtained for
this retrospective analysis, and key data that were collected
included capecitabine dose by cycle; adverse event data for
hematological events (neutropenia, leukopenia, thrombo-
cytopenia, anemia), cardiac events (angina pectoris, heart
failure, myocardial infarction, arrhythmia/conduction dis-
order, myocarditis, ECG changes), hand-foot syndrome,
and gastrointestinal (GI) events (diarrhea, nausea, vomit-
ing, constipation, mucositis, abdominal pain, stomatitis,
loss of appetite); and dose reductions and discontinuations.
Patient data were excluded if the patient received anti-
cancer therapy other than capecitabine, and only the first
eight cycles of therapy were retained for patients who
received more than eight cycles of therapy or an additional
eight cycles at a later start date.
For the adverse event analyses, patients were counted if
they had the adverse event concerned and if they had a dose
reduction or discontinuation of treatment during that cycle.
The cause of dose reduction or discontinuation was not
explicitly stated to be the adverse event in question but was
tracked for the patients who had that adverse event in that
cycle. Discontinuation in cycle 8 could be due to adverse
events, progression, or simply the end of planned treat-
ment. This analysis has not looked beyond eight cycles, but
some patients were treated for much longer than eight
cycles.
Relative dose intensity (RDI) was calculated for each
patient to determine the dose received relative to the
planned schedule to dose over eight cycles. Receipt of the
starting dose for eight cycles represented 100%. Reduced
doses were scored based on their relative proportion of the
starting dose. For example, if 1250 mg/m2 twice daily was
the starting dose, then a reduction to 1000 mg/m2 was
scored as 80% of the dose for that cycle, and a reduction
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from 1000 to 750 mg/m2 was scored as 75% of the dose for
that cycle. RDI was calculated as the number of cycles at
the starting dose plus the number of cycles at a reduced
dose (e.g. four cycles 9 1.0 ? four cycles 9 0.8) divided
by eight total cycles.
3 Results
Data for 86 patients (45 female, 41 male; mean age at start
of treatment, 69 years [range 45–83]; 57% C70 years of
age) treated with capecitabine monotherapy for mCRC
between 2009 and 2013 were analyzed for side effects
occurring during eight planned cycles of treatment. A total
of 355 patients started palliative systemic therapy for
mCRC at our center during this time period. Twelve
patients started cycle 1 with a dose of 750 mg/m2 twice
daily (mean age 64.4 years), 54 patients started at a dose of
1000 mg/m2 twice daily (mean age 71.5 years), and 20
patients started at a dose of 1250 mg/m2 twice daily (mean
age 67 years). In total, 35 patients were still taking cape-
citabine in cycle 8 (Table 1), of whom 49% were on the
lowest dose. A total of 41% of patients completed at least
four cycles of therapy at the starting dose, and 21% com-
pleted eight cycles of therapy at the starting dose. The
numbers of patients on the lowest dose stayed relatively
constant or increased as patients moved from higher doses
in the later cycles of therapy.
3.1 Relative Dose Intensity
A box plot of the RDIs for all 86 patients included in the
study is shown in Fig. 1. The median RDIs for patients who
started at the 750, 1000, and 1250 mg/m2 twice-daily doses
were 37.5, 67.2, and 68.75%, respectively. Twenty-five
percent of patients at the 750 mg/m2 twice-daily dose
received 100% of the planned dose compared with 18.5%
of patients at the 1000 mg/m2 twice-daily dose, and 30% of
patients at the 1250 mg/m2 dose.
3.2 Rates of Hand-Foot Syndrome
HFS events were common in all cycles and at all dose
levels. A total of 46.5% of patients experienced HFS at
some time during treatment (Fig. 2a). Newly developing
HFS was observed in all cycles, and persistent or recurrent
HFS events were responsible for 54.5% of total HFS events
(n = 88 events). HFS events appeared to increase over time
for patients at all three doses (Fig. 2b), which is most
clearly seen at the 1000 mg/m2 dose. After the first cycle
(8.1% HFS reported), 15–32% of patients reported HFS in
each cycle. Over the course of eight cycles, 22 patients had
dose reductions and 15 discontinued treatment during a
cycle in which they reported HFS, often within four cycles
of treatment (Table 2).
3.3 Rates of Gastrointestinal Adverse Events
GI events were common in all cycles (Fig. 3a), and most
first-time events were in the first three cycles. A total of
44.2% of patients experienced a GI adverse event at some
time during treatment. In any given cycle, between 14 and
25% of patients reported GI events. Persistent or recurring
GI events accounted for 54.8% of total GI events (n = 84
events). Evaluation of GI events by dose level showed that
more patients at the 750 mg/m2 dose level experienced GI
events in later cycles, while these events were less common
for patients at the 1000 mg/m2 dose level and were not
observed for patients at the 1250 mg/m2 dose in cycles 4–8
(Fig. 3b). Over the course of eight cycles, 13 patients had
dose reductions and 21 discontinued treatment during a
cycle in which they reported a GI event (Table 3). Most of
these treatment modifications were performed in the first
four cycles of capecitabine therapy. The most common GI
Table 1 Number of patients starting each cycle, by dose
Cycle 750 mg/m2 1000 mg/m2 1250 mg/m2 Total
1 12 54 20 86
2 11 47 18 76
3 12 40 12 64
4 15 27 10 52
5 15 22 8 45
6 16 19 7 42
7 16 14 7 37
8 17 11 7 35
Fig. 1 Relative dose intensities for patient data evaluated over the
course of eight planned cycles of oral capecitabine monotherapy.
Boxes represent interquartile range (25th–75th quartiles), with
median value indicated. Whiskers represent maximum and minimum
relative dose intensity values for patients at each starting dose
(750 mg/m2 bid, n = 12; 1000 mg/m2 bid, n = 54; 1250 mg/m2 bid,
n = 20). bid twice daily
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events were diarrhea, nausea, vomiting, and abdominal
pain (Table 4).
A comparison of the total percentage of patients affected
by either HFS or a GI event over eight cycles is shown in
Fig. 4.
3.4 Rates of Hematological and Cardiac Adverse
Events
Six hematological adverse events occurred in five patients
during the first four cycles of therapy. One patient at the
1250 mg/m2 dose had neutropenia in cycle 1 that was
treated with a dose interruption and dose reduction to
1000 mg/m2 in cycle 2. The patient experienced neu-
tropenia again in cycle 2 but without dose adjustments.
One patient each at the 1000 mg/m2 dose experienced
leukopenia and thrombocytopenia in the third cycle.
Leukopenia was managed with a dose interruption in that
cycle and the thrombocytopenia was managed with a dose
reduction to 750 mg/m2. One patient at the 750 mg/m2
dose experienced anemia in cycle 2, and one patient at the
1000 mg/m2 dose experienced anemia in cycle 4. The
patient discontinued in this cycle but the recorded data did
not explicitly state that anemia was the cause.
Six cardiotoxicity events were reported in five patients
(mean age 71 years), i.e. chest pain, unregulated heartbeat,
a
b
Fig. 2 Rates of HFS by cycle: a all patients (n = 86) and b according
to dose (twice daily). Percentages were calculated as the number of
patients who had HFS, of the number of patients who started
treatment at that dose level for that cycle. A total of 27 patients
experienced HFS at the 750 mg/m2 twice-daily dose, 45 at the
1000 mg/m2 dose, and 16 at the 1250 mg/m2 dose over the course of
treatment. HFS hand-foot syndrome
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atrial fibrillation with pulmonary embolism, dyspnea on
exertion and cough, arrhythmia/conduction disorder. Five
of these were at the 1000 mg/m2 dose, and atrial fibrillation
recurred in one patient who had been reduced to the
750 mg/m2 dose in a different cycle. There was one dose
reduction and one discontinuation among patients who
reported a cardiac adverse event for that cycle.
4 Discussion
An important and ongoing point of attention influencing
treatment outcomes for cancer patients is the tolerability of
chemotherapeutic drugs. This is even more important in the
palliative setting. The gold standard in clinical research is
to investigate these questions in randomized controlled
clinical trials but these are expensive and cumbersome trial
designs and are rarely suitable for assessing daily practical
questions. A good alternative to get more insight into these
types of questions is with so-called real-world studies. In
this real-world study, a retrospective analysis was per-
formed on data from patients treated for eight planned
cycles of therapy with a commonly used chemotherapeutic
drug (capecitabine) for mCRC. We chose to analyze only
patients receiving capecitabine monotherapy to reduce
unwanted interactions and influence by other anticancer
drugs in the treatment. We were able to evaluate the rates
of adverse events in patients for whom treatment was
selected based on each patient’s clinical situation and
personal preference in real-world oncology treatment
decision-making situations rather than based on selective
clinical trial inclusion criteria.
In this study, we have evaluated dosing adjustments and
adverse events in patients treated with capecitabine
monotherapy for mCRC. We evaluated rates of occurrence
and persistence of HFS, GI events, hematological adverse
events, and cardiotoxicity over the course of eight sched-
uled cycles of capecitabine monotherapy and rates of dose
reductions and discontinuation. The rates of adverse events
reported in this study are similar to those of reported
clinical trials of capecitabine monotherapy. The rate of
HFS in this study (46.5% overall) is consistent with rates
observed in phase III clinical trials of 30–53.5% [4, 8, 10]
and with the rate of 42% reported in an observational study
that included patients who received capecitabine as
monotherapy or in combination treatment [14]. The rate of
GI events in this study was 44.2%; previous studies have
reported that between 11 and 50% of patients experience
one GI event, including diarrhea, vomiting, nausea, or
abdominal pain, while receiving capecitabine monotherapy
[4, 8, 10]. Our results are consistent with these findings.
Neutropenia, observed in only one patient in this study
(1.1%) has been reported to occur in 1% of patients in
clinical trials [4, 8]. Rates of other hematological adverse
events were also low in this study, similar to previous
studies [4, 8, 10]. Cardiotoxicity, observed in 5% of
patients in this study, was either very rare (approximately
1%) or not reported due to occurring at lower than the 5%
threshold for reporting in previous studies [4, 8, 10]. It was
not possible to establish if this difference could be
explained by the current population being more frail than
those described in previous controlled trials.
Most patients in this study (77%) started under the
approved dose of 1250 mg/m2 twice daily, 63% started at
1000 mg/m2 twice daily, and 14% started at 750 mg/m2
twice daily. Of note, the reduced starting doses used here are
not the recommended reduced starting doses for special
populations (75% of starting dose for renal impairment) [9],
and phase III trials evaluated a starting dose of 1250 mg/m2
twice daily or used 1000 mg/m2 twice daily in elderly
patients C70 years of age [4, 8, 10]. Patients in this study
who received the 1000 mg/m2 twice-daily dose had a mean
age of 71.5 years, consistent with age as an explanation for
the use of this reduced dose. However, patients in the study
who received 750 mg/m2 twice daily had a mean age of
64.4 years, suggesting that this population was considered
frail by their physician. Although this suggests that physi-
cians are reducing the starting dose of capecitabine in
anticipation of adverse events, our real-world data did not
provide an explicit explanation for these treatment decisions.
Dose reductions and treatment discontinuations were
common in this study, occurring in 17–24% of patients
who experienced HFS and 15–25% of patients who expe-
rienced a GI event. Dose reductions or cessation of treat-
ment most likely due to adverse events occurred
predominantly within the first four cycles of therapy.
Timely recognition and management of the clinically rel-
evant HFS and GI toxicity is therefore of utmost impor-
tance in order to prevent early termination of treatment.
Table 2 Number of dose reductions or discontinuations in patients




1 7 1 2
2 12 2 1
3 16 6 2
4 15 3 4
5 9 2 1
6 8 1 1
7 12 4 1
8 9 2 3
Total 88 21 15
HFS hand-foot syndrome
a New, persisting, or recurring HFS events
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Cassidy et al. reported that 34% of patients starting
treatment at 1250 mg/m2 twice daily required a dose
reduction for adverse events, while Cunningham et al.
reported that 15% of elderly patients who started capeci-
tabine treatment at 1000 mg/m2 twice daily discontinued
due to adverse events [4, 8]. In addition, Feliu et al.
reported that dose delays occurred in 18% of elderly
patients treated with capecitabine 1250 mg/m2 twice daily
[9]. In our analysis, the occurrence of HFS and GI events
was not related to the dose of capecitabine, which may
suggest that lower starting doses and dose reductions do
not improve adverse event rates, nor do they prevent them
from occurring. In an observational study by Stein et al.,
the incidence of HFS increased with duration of treatment
and was higher in younger patients than in older patients
(46 vs. 37%; p = 0.0014) despite similar median daily
doses of capecitabine [14].
It is unclear whether dose reductions might negatively
impact efficacy outcomes. Cassidy et al. reported a similar
risk of disease progression in patients who required dose
modification while receiving capecitabine monotherapy
compared with those who did not, while patients who
required dose modifications while taking 5-fluorouracil/
leucovorin had a 12% higher risk of disease progression
[4]. Stein et al. reported that patients who experienced HFS
had higher response rates, progression-free survival (PFS),
a
b
Fig. 3 Rates of GI events by cycle: a all patients (n = 86) and
b according to dose (twice daily). Percentages were calculated as the
number of patients who had a GI event, of the number of patients who
started treatment at that dose level for that cycle. A total of 30 patients
experienced a GI event at the 750 mg/m2 twice-daily dose, 50 at the
1000 mg/m2 dose, and 4 at the 1250 mg/m2 dose over the course of
treatment. GI gastrointestinal
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and overall survival (OS) than patients without HFS. The
authors postulated that a trend in improved PFS and OS in
patients who received a capecitabine dose reduction might
be related to the occurrence of HFS in this population [14].
This study provides some insights into the clinical
decisions that were considered necessary in the best
interests of the patient and what impact these decisions had
on the dosing and schedule of capecitabine. However, there
were significant limitations of this study, including its
small size, its retrospective nature and lack of control
group, and the quality of the real-world data we were able
to obtain. The patient record data used in this study often
did not include clear reasons for treatment discontinuation
or dose reductions, therefore these could not be directly
correlated to adverse events. In addition, they did not
include consistent information on the grade of adverse
events, which would have been informative.
5 Conclusions
This study has provided important information on the rates
of adverse events and dosing practices in patients sched-
uled to be treated with eight cycles of capecitabine
monotherapy for mCRC in a real-world setting. The most
frequently occurring adverse events were HFS and GI
toxicity. These adverse events often led to dose reductions
or even termination of treatment, possibly impairing the
benefit of fluoropyrimidines in these patients. This infor-
mation should be of value to practitioners who treat
patients with mCRC, particularly older or frail patients.
Table 3 Number of dose reductions or discontinuations in patients




1 17 3 1
2 19 3 7
3 13 2 4
4 8 1 3
5 7 1 0
6 6 0 1
7 8 3 1
8 6 0 4
Total 84 13 21
GI gastrointestinal
a New, persisting, or recurring GI events
Table 4 Gastrointestinal events by type (n = 86)








Decreased appetite 1 (1.2)
a Numbers represent all patients who had that gastrointestinal event
in any cycle, but not recurrent events
Fig. 4 Rates of GI events and HFS by cycle, all patients (n = 86). GI gastrointestinal, HFS hand-foot syndrome
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